|
Volumn 354, Issue , 2016, Pages
|
Problems with ethical approval and how to fix them: Lessons from three trials in rheumatoid arthritis
|
Author keywords
[No Author keywords available]
|
Indexed keywords
METHOTREXATE;
NONSTEROID ANTIINFLAMMATORY AGENT;
OCRELIZUMAB;
ANTIRHEUMATIC AGENT;
MONOCLONAL ANTIBODY;
ACCESS TO INFORMATION;
ARTICLE;
CLINICAL PROTOCOL;
DOCUMENTATION;
DRUG EFFICACY;
DRUG TREATMENT FAILURE;
ETHICAL APPROVAL;
ETHICS;
HOMEOPATHY;
HUMAN;
INFORMATION DISSEMINATION;
INFORMED CONSENT;
METHODOLOGY;
PRIORITY JOURNAL;
PROTOCOL COMPLIANCE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RHEUMATOID ARTHRITIS;
RISK;
ARTHRITIS, RHEUMATOID;
CLINICAL TRIAL (TOPIC);
DRUG INDUSTRY;
PROCEDURES;
PROFESSIONAL STANDARD;
RISK MANAGEMENT;
UNITED KINGDOM;
ACCESS TO INFORMATION;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
CLINICAL TRIALS AS TOPIC;
DOCUMENTATION;
DRUG INDUSTRY;
ETHICS COMMITTEES;
HOMEOPATHY;
HUMANS;
INFORMED CONSENT;
RISK MANAGEMENT;
UNITED KINGDOM;
|
EID: 84987621858
PISSN: 09598146
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.i4626 Document Type: Article |
Times cited : (7)
|
References (8)
|